Antifungal Drugs Market By Drug Class (Echinocandins, Azoles, Polyenes, Allylamines, Others), By Infection Type (Superficial Antifungal Infections, Systemic Antifungal Infections), By Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others), By Dosage Forms (Oral, Topical, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

Antifungal Drugs Market

Antifungal drugs are medications that selectively eliminate fungal infections from the host. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is continuously growing and evolving owing to robust developmental efforts made by researchers and market players in the field.

Factors that drive the growth of the global anti-fungal drugs market are growth in prevalence of fungal infection, rise in awareness levels pertaining to myriad of fungal infections, and increase in demand for generic drugs. Moreover, the production of antifungal drugs by key players such as GlaxosmithKline Plc manufactures, performs R&D activities, and develops innovative products applicable in the six end core areas, respiratory, HIV &infectious diseases, vaccines, immuno-inflammation, oncology, and rare diseases. It offers more products to improve the treatment for patients, consumers, and healthcare providers. It has a significant global presence in more than 150 countries. It manufactures antifungal creams, Clioquinol, Miconazole, Nystatin, Oxiconazole, and Terbinafine. With these antifungal drugs, GSK sustains its market presence in the global antifungal drugs market.

For instance, in June 2021, Mankind Pharma announced the launch of drug named Posaconazole Gastro. They are the resistant tablets, which are used to treat black fungus. In addition, in June 2021, Cadila Pharmaceuticals launched a new triazoel antifungal drug Posaconazole that is effective against a wide range of invasive fungal diseases. In addition the drug has been recommended as a second-line treatment for mucormycosis. Thus, rise in production of new antifungal drugs by large number of key players has increased the growth of the market.

Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the anti-fungal drugs market. In addition, Fungal Genetic Resource of India (FUNGEN) was engaged in training graduate student mycologists in colleges and universities in isolation techniques, and operating on a crowdsourcing model with “mini-collections” developed at participating centers to provide awareness about fungus, the diseases caused by them, and the treatments. Hence, such robust initiatives taken by nongovernmental organizations are expected to fuel the market growth.

The global antifungal drugs industry is segmented into drugs class, infection type, therapeutic indication type, and dosage forms. On the basis of drug class, the azoles segment is anticipated to maintain its dominance during the forecast period.  This is due to the high usage of drugs such as azole for all the fungal indications and these also offer broad spectrum activity and improved safety levels. In addition, rise in prevalence of most commonly occurring systematic fungal infection such as candidiasis supplements the antifungal drugs market growth. However, the echinocandins are expected to grow rapidly throughout the forecast period. This is owing to the growth in incidence of hospital-acquired infections and increase in life expectancy among people.

The candidiasis indication is expected to register the highest CAGR of 3.7 throughout the forecast period. This is due to high incidences of skin infections in both children and adults. Aspergillosis segment generated the highest revenue in 2020, accounting for about 4.1% of the total share in 2020.

Region wise, the antifungal drugs industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Region wise, North America accounted for a majority share of the global antifungal market in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to surge in prevalence of infectious diseases such as aspergillosis, dermatophytosis, and candidiasis; increase in number of approvals for anti-fungal drugs; and presence of key players. Asia-Pacific is anticipated to witness highest CAGR during antifungal drugs market forecast owing to growth in healthcare expenditures.

KEY FINDINGS OF THE STUDY

Depending upon antifungal drugs market analysis, azoles segment among Drug class was the highest contributor in 2020.

On the basis of infection type, systematic antifungal infection dominated the market in 2020, and is expected to continue this trend during the forecast period.

On the basis of Therapeutic indication type, candidiasis dominated the market in 2020, and is expected to continue this trend during the forecast period.

By dosage forms, oral segment dominated the market in 2020, and is expected to continue this trend during the forecast period

By Region, North America accounted for a majority of the antifungal drugs market share in 2020, and is anticipated to remain dominant during the forecast period.

Overview

The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030. Antifungal drugs are used to treat fungal infections, which occur due to unclean, humid, and unhygienic environments. These infections are caused by organisms, which live by feeding on living tissue and are commonly known as dermatophytes that are responsible for the infection of hair, skin, and nail as they can utilize keratin. In addition, fungal infections can cause harm to superficial (skin, mouth, and vagina) and systemic parts of the body (lungs, bones, brain, eyes, and others). Some of the common fungal infections such as athlete’s foot, fungal meningitis, ringworm, and other infections can be treated by antifungal drugs that work by killing the fungal cells, breaking the contents of the cells. These cells eventually leak out and result in the death of the cell, which also prevent the cell to grow further, thus preventing the infection.

Growth of the anti-fungal drugs market is majorly driven by alarming rise in prevalence of chronic diseases such as diabetes and tuberculosis drives the growth of the market. In addition, growth in incidence &prevalence rate of infectious diseases and growth in population of immuno-compromised (prone to infectious diseases) individuals contribute toward the growth of the market. Furthermore, presence of alternative therapies and slow growth of medical infrastructure in emerging economies, such as China and India, hinder the market growth during the forecast period. Moreover, as per Centers for Disease Control and Prevention (CDC) estimates, there are roughly 46,000 cases of hospital-associated invasive candidiasis each year, a number that is increasing over the past two decades. Hospital-associated invasive candidiasis is among the most common bloodstream infections found in hospitalized patients, and is caused by Candida yeasts that generally dwell in the gut and on the skin with some problems. This disease has led to death in about 30% of patients with bloodstream infections. Most cases of candidiasis fungal infection occur in the U.S. and Canada. In states where blastomycosis is reportable, yearly incidence rates are approximately 1 to 2 cases per 100,000 people. In addition, surgein healthcare expenditure; availability of skilled professionals; collaborations & partnerships between key players to facilitate drug development; rise in R&D activities to improve quality of drugs are the factors that propel the market growth. Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.

The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region. By drug type, it is divided into echinocandins, azoles, polyenes, allylamines, and other drugs. By therapeutic indication, it is classified into aspergillosis, dermatophytosis, candidiasis, and others. By infection type, the market is bifurcated into superficial and systemic antifungals.

By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2020, and is expected to maintain the dominance throughout the forecast period. This is attributed to the increase in prevalence of fungal infections and growth in development of antifungal biopharmaceuticals. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, due to the improvement in healthcare facilities, available disposable income, and rapid development of economic conditions. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global anti-fungal drugs market are Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Merck & Co. Inc, Novaris AG, Abbott Laboratories, GlaxosithKlinePlc, AstellasPharma Inc., Johnson & Johnson and Merz Pharma.

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global anti-fungal drugs market to identify the prevailing opportunities.

This study presents the competitive landscape of the global market to predict the competitive environment across geographies.

Comprehensive analysis of factors that drive and restrict the market growth is provided.

Region & country-wise analysis is provided to understand the market trends and dynamics.

Key Market Segments

General Electric Compan

Scope of Antifungal Drugs Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Echinocandins

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Azoles

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Polyenes

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Allylamines

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

4.6 Others

4.6.1 Key market trends, growth factors and opportunities

4.6.2 Market size and forecast, by region

4.6.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Superficial Antifungal Infections

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Systemic Antifungal Infections

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Aspergillosis

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Dermatophytosis

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.4 Candidiasis

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

6.5 Others

6.5.1 Key market trends, growth factors and opportunities

6.5.2 Market size and forecast, by region

6.5.3 Market analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 Oral

7.2.1 Key market trends, growth factors and opportunities

7.2.2 Market size and forecast, by region

7.2.3 Market analysis by country

7.3 Topical

7.3.1 Key market trends, growth factors and opportunities

7.3.2 Market size and forecast, by region

7.3.3 Market analysis by country

7.4 Others

7.4.1 Key market trends, growth factors and opportunities

7.4.2 Market size and forecast, by region

7.4.3 Market analysis by country

8.1 Overview

8.1.1 Market size and forecast

8.2 North America

8.2.1 Key trends and opportunities

8.2.2 North America Market size and forecast, by Drug Class

8.2.3 North America Market size and forecast, by Infection Type

8.2.4 North America Market size and forecast, by Therapeutic Indications

8.2.5 North America Market size and forecast, by Dosage Forms

8.2.6 North America Market size and forecast, by country

8.2.6.1 U.S.

8.2.6.1.1 Market size and forecast, by Drug Class

8.2.6.1.2 Market size and forecast, by Infection Type

8.2.6.1.3 Market size and forecast, by Therapeutic Indications

8.2.6.1.4 Market size and forecast, by Dosage Forms

8.2.6.2 Canada

8.2.6.2.1 Market size and forecast, by Drug Class

8.2.6.2.2 Market size and forecast, by Infection Type

8.2.6.2.3 Market size and forecast, by Therapeutic Indications

8.2.6.2.4 Market size and forecast, by Dosage Forms

8.2.6.3 Mexico

8.2.6.3.1 Market size and forecast, by Drug Class

8.2.6.3.2 Market size and forecast, by Infection Type

8.2.6.3.3 Market size and forecast, by Therapeutic Indications

8.2.6.3.4 Market size and forecast, by Dosage Forms

8.3 Europe

8.3.1 Key trends and opportunities

8.3.2 Europe Market size and forecast, by Drug Class

8.3.3 Europe Market size and forecast, by Infection Type

8.3.4 Europe Market size and forecast, by Therapeutic Indications

8.3.5 Europe Market size and forecast, by Dosage Forms

8.3.6 Europe Market size and forecast, by country

8.3.6.1 Germany

8.3.6.1.1 Market size and forecast, by Drug Class

8.3.6.1.2 Market size and forecast, by Infection Type

8.3.6.1.3 Market size and forecast, by Therapeutic Indications

8.3.6.1.4 Market size and forecast, by Dosage Forms

8.3.6.2 France

8.3.6.2.1 Market size and forecast, by Drug Class

8.3.6.2.2 Market size and forecast, by Infection Type

8.3.6.2.3 Market size and forecast, by Therapeutic Indications

8.3.6.2.4 Market size and forecast, by Dosage Forms

8.3.6.3 United Kingdom

8.3.6.3.1 Market size and forecast, by Drug Class

8.3.6.3.2 Market size and forecast, by Infection Type

8.3.6.3.3 Market size and forecast, by Therapeutic Indications

8.3.6.3.4 Market size and forecast, by Dosage Forms

8.3.6.4 Italy

8.3.6.4.1 Market size and forecast, by Drug Class

8.3.6.4.2 Market size and forecast, by Infection Type

8.3.6.4.3 Market size and forecast, by Therapeutic Indications

8.3.6.4.4 Market size and forecast, by Dosage Forms

8.3.6.5 Spain

8.3.6.5.1 Market size and forecast, by Drug Class

8.3.6.5.2 Market size and forecast, by Infection Type

8.3.6.5.3 Market size and forecast, by Therapeutic Indications

8.3.6.5.4 Market size and forecast, by Dosage Forms

8.3.6.6 Rest of Europe

8.3.6.6.1 Market size and forecast, by Drug Class

8.3.6.6.2 Market size and forecast, by Infection Type

8.3.6.6.3 Market size and forecast, by Therapeutic Indications

8.3.6.6.4 Market size and forecast, by Dosage Forms

8.4 Asia-Pacific

8.4.1 Key trends and opportunities

8.4.2 Asia-Pacific Market size and forecast, by Drug Class

8.4.3 Asia-Pacific Market size and forecast, by Infection Type

8.4.4 Asia-Pacific Market size and forecast, by Therapeutic Indications

8.4.5 Asia-Pacific Market size and forecast, by Dosage Forms

8.4.6 Asia-Pacific Market size and forecast, by country

8.4.6.1 Japan

8.4.6.1.1 Market size and forecast, by Drug Class

8.4.6.1.2 Market size and forecast, by Infection Type

8.4.6.1.3 Market size and forecast, by Therapeutic Indications

8.4.6.1.4 Market size and forecast, by Dosage Forms

8.4.6.2 China

8.4.6.2.1 Market size and forecast, by Drug Class

8.4.6.2.2 Market size and forecast, by Infection Type

8.4.6.2.3 Market size and forecast, by Therapeutic Indications

8.4.6.2.4 Market size and forecast, by Dosage Forms

8.4.6.3 Australia

8.4.6.3.1 Market size and forecast, by Drug Class

8.4.6.3.2 Market size and forecast, by Infection Type

8.4.6.3.3 Market size and forecast, by Therapeutic Indications

8.4.6.3.4 Market size and forecast, by Dosage Forms

8.4.6.4 India

8.4.6.4.1 Market size and forecast, by Drug Class

8.4.6.4.2 Market size and forecast, by Infection Type

8.4.6.4.3 Market size and forecast, by Therapeutic Indications

8.4.6.4.4 Market size and forecast, by Dosage Forms

8.4.6.5 South Korea

8.4.6.5.1 Market size and forecast, by Drug Class

8.4.6.5.2 Market size and forecast, by Infection Type

8.4.6.5.3 Market size and forecast, by Therapeutic Indications

8.4.6.5.4 Market size and forecast, by Dosage Forms

8.4.6.6 Rest of Asia-Pacific

8.4.6.6.1 Market size and forecast, by Drug Class

8.4.6.6.2 Market size and forecast, by Infection Type

8.4.6.6.3 Market size and forecast, by Therapeutic Indications

8.4.6.6.4 Market size and forecast, by Dosage Forms

8.5 LAMEA

8.5.1 Key trends and opportunities

8.5.2 LAMEA Market size and forecast, by Drug Class

8.5.3 LAMEA Market size and forecast, by Infection Type

8.5.4 LAMEA Market size and forecast, by Therapeutic Indications

8.5.5 LAMEA Market size and forecast, by Dosage Forms

8.5.6 LAMEA Market size and forecast, by country

8.5.6.1 Brazil

8.5.6.1.1 Market size and forecast, by Drug Class

8.5.6.1.2 Market size and forecast, by Infection Type

8.5.6.1.3 Market size and forecast, by Therapeutic Indications

8.5.6.1.4 Market size and forecast, by Dosage Forms

8.5.6.2 Saudi Arabia

8.5.6.2.1 Market size and forecast, by Drug Class

8.5.6.2.2 Market size and forecast, by Infection Type

8.5.6.2.3 Market size and forecast, by Therapeutic Indications

8.5.6.2.4 Market size and forecast, by Dosage Forms

8.5.6.3 South Africa

8.5.6.3.1 Market size and forecast, by Drug Class

8.5.6.3.2 Market size and forecast, by Infection Type

8.5.6.3.3 Market size and forecast, by Therapeutic Indications

8.5.6.3.4 Market size and forecast, by Dosage Forms

8.5.6.4 Rest of LAMEA

8.5.6.4.1 Market size and forecast, by Drug Class

8.5.6.4.2 Market size and forecast, by Infection Type

8.5.6.4.3 Market size and forecast, by Therapeutic Indications

8.5.6.4.4 Market size and forecast, by Dosage Forms

9.1. Introduction

9.2. Top winning strategies

9.3. Product Mapping of Top 10 Player

9.4. Competitive Dashboard

9.5. Competitive Heatmap

9.6. Key developments

10.1 Hologic, Inc

10.1.1 Company overview

10.1.2 Company snapshot

10.1.3 Operating business segments

10.1.4 Product portfolio

10.1.5 Business performance

10.1.6 Key strategic moves and developments

10.2 Koninklijke Philips N.V.

10.2.1 Company overview

10.2.2 Company snapshot

10.2.3 Operating business segments

10.2.4 Product portfolio

10.2.5 Business performance

10.2.6 Key strategic moves and developments

10.3 Quest Diagnostics Incorporated

10.3.1 Company overview

10.3.2 Company snapshot

10.3.3 Operating business segments

10.3.4 Product portfolio

10.3.5 Business performance

10.3.6 Key strategic moves and developments

10.4 Siemens Medical Solutions USA, Inc.

10.4.1 Company overview

10.4.2 Company snapshot

10.4.3 Operating business segments

10.4.4 Product portfolio

10.4.5 Business performance

10.4.6 Key strategic moves and developments

10.5 bioMérieux SA

10.5.1 Company overview

10.5.2 Company snapshot

10.5.3 Operating business segments

10.5.4 Product portfolio

10.5.5 Business performance

10.5.6 Key strategic moves and developments

10.6 Abbott

10.6.1 Company overview

10.6.2 Company snapshot

10.6.3 Operating business segments

10.6.4 Product portfolio

10.6.5 Business performance

10.6.6 Key strategic moves and developments

10.7 BD

10.7.1 Company overview

10.7.2 Company snapshot

10.7.3 Operating business segments

10.7.4 Product portfolio

10.7.5 Business performance

10.7.6 Key strategic moves and developments

10.8 Cardinal Health, Inc.

10.8.1 Company overview

10.8.2 Company snapshot

10.8.3 Operating business segments

10.8.4 Product portfolio

10.8.5 Business performance

10.8.6 Key strategic moves and developments

10.9 F. Hoffmann-La Roche Ltd

10.9.1 Company overview

10.9.2 Company snapshot

10.9.3 Operating business segments

10.9.4 Product portfolio

10.9.5 Business performance

10.9.6 Key strategic moves and developments

10.10 General Electric Company

10.10.1 Company overview

10.10.2 Company snapshot

10.10.3 Operating business segments

10.10.4 Product portfolio

10.10.5 Business performance

10.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 2. ANTIFUNGAL DRUGS MARKET REVENUE, FOR ECHINOCANDINS, BY REGION , 2020-2030,($MILLION)

TABLE 3. ANTIFUNGAL DRUGS MARKET ECHINOCANDINS BY COUNTRY, 2020-2030,($MILLION)

TABLE 4. ANTIFUNGAL DRUGS MARKET REVENUE, FOR AZOLES, BY REGION , 2020-2030,($MILLION)

TABLE 5. ANTIFUNGAL DRUGS MARKET AZOLES BY COUNTRY, 2020-2030,($MILLION)

TABLE 6. ANTIFUNGAL DRUGS MARKET REVENUE, FOR POLYENES, BY REGION , 2020-2030,($MILLION)

TABLE 7. ANTIFUNGAL DRUGS MARKET POLYENES BY COUNTRY, 2020-2030,($MILLION)

TABLE 8. ANTIFUNGAL DRUGS MARKET REVENUE, FOR ALLYLAMINES, BY REGION , 2020-2030,($MILLION)

TABLE 9. ANTIFUNGAL DRUGS MARKET ALLYLAMINES BY COUNTRY, 2020-2030,($MILLION)

TABLE 10. ANTIFUNGAL DRUGS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 11. ANTIFUNGAL DRUGS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 12. GLOBAL ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 13. ANTIFUNGAL DRUGS MARKET REVENUE, FOR SUPERFICIAL ANTIFUNGAL INFECTIONS, BY REGION , 2020-2030,($MILLION)

TABLE 14. ANTIFUNGAL DRUGS MARKET SUPERFICIAL ANTIFUNGAL INFECTIONS BY COUNTRY, 2020-2030,($MILLION)

TABLE 15. ANTIFUNGAL DRUGS MARKET REVENUE, FOR SYSTEMIC ANTIFUNGAL INFECTIONS, BY REGION , 2020-2030,($MILLION)

TABLE 16. ANTIFUNGAL DRUGS MARKET SYSTEMIC ANTIFUNGAL INFECTIONS BY COUNTRY, 2020-2030,($MILLION)

TABLE 17. GLOBAL ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2020-2030,($MILLION)

TABLE 18. ANTIFUNGAL DRUGS MARKET REVENUE, FOR ASPERGILLOSIS, BY REGION , 2020-2030,($MILLION)

TABLE 19. ANTIFUNGAL DRUGS MARKET ASPERGILLOSIS BY COUNTRY, 2020-2030,($MILLION)

TABLE 20. ANTIFUNGAL DRUGS MARKET REVENUE, FOR DERMATOPHYTOSIS, BY REGION , 2020-2030,($MILLION)

TABLE 21. ANTIFUNGAL DRUGS MARKET DERMATOPHYTOSIS BY COUNTRY, 2020-2030,($MILLION)

TABLE 22. ANTIFUNGAL DRUGS MARKET REVENUE, FOR CANDIDIASIS, BY REGION , 2020-2030,($MILLION)

TABLE 23. ANTIFUNGAL DRUGS MARKET CANDIDIASIS BY COUNTRY, 2020-2030,($MILLION)

TABLE 24. ANTIFUNGAL DRUGS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 25. ANTIFUNGAL DRUGS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 26. GLOBAL ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2020-2030,($MILLION)

TABLE 27. ANTIFUNGAL DRUGS MARKET REVENUE, FOR ORAL, BY REGION , 2020-2030,($MILLION)

TABLE 28. ANTIFUNGAL DRUGS MARKET ORAL BY COUNTRY, 2020-2030,($MILLION)

TABLE 29. ANTIFUNGAL DRUGS MARKET REVENUE, FOR TOPICAL, BY REGION , 2020-2030,($MILLION)

TABLE 30. ANTIFUNGAL DRUGS MARKET TOPICAL BY COUNTRY, 2020-2030,($MILLION)

TABLE 31. ANTIFUNGAL DRUGS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)

TABLE 32. ANTIFUNGAL DRUGS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)

TABLE 33. ANTIFUNGAL DRUGS MARKET, BY REGION, 2020-2030,($MILLION)

TABLE 34. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 35. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 36. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2020-2030,($MILLION)

TABLE 37. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2020-2030,($MILLION)

TABLE 38. NORTH AMERICA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 39. U.S. ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 40. U.S. ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 41. U.S. ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 42. U.S. ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 43. CANADA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 44. CANADA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 45. CANADA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 46. CANADA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 47. MEXICO ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 48. MEXICO ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 49. MEXICO ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 50. MEXICO ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 51. EUROPE ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 52. EUROPE ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 53. EUROPE ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2020-2030,($MILLION)

TABLE 54. EUROPE ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2020-2030,($MILLION)

TABLE 55. EUROPE ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 56. GERMANY ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 57. GERMANY ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 58. GERMANY ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 59. GERMANY ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 60. FRANCE ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 61. FRANCE ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 62. FRANCE ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 63. FRANCE ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 64. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 65. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 66. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 67. UNITED KINGDOM ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 68. ITALY ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 69. ITALY ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 70. ITALY ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 71. ITALY ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 72. SPAIN ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 73. SPAIN ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 74. SPAIN ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 75. SPAIN ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 76. REST OF EUROPE ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 77. REST OF EUROPE ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 78. REST OF EUROPE ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 79. REST OF EUROPE ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 80. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 81. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 82. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2020-2030,($MILLION)

TABLE 83. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2020-2030,($MILLION)

TABLE 84. ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 85. JAPAN ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 86. JAPAN ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 87. JAPAN ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 88. JAPAN ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 89. CHINA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 90. CHINA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 91. CHINA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 92. CHINA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 93. AUSTRALIA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 94. AUSTRALIA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 95. AUSTRALIA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 96. AUSTRALIA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 97. INDIA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 98. INDIA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 99. INDIA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 100. INDIA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 101. SOUTH KOREA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 102. SOUTH KOREA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 103. SOUTH KOREA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 104. SOUTH KOREA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 105. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 106. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 107. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 108. REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 109. LAMEA ANTIFUNGAL DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 110. LAMEA ANTIFUNGAL DRUGS MARKET, BY INFECTION TYPE, 2020-2030,($MILLION)

TABLE 111. LAMEA ANTIFUNGAL DRUGS MARKET, BY THERAPEUTIC INDICATIONS, 2020-2030,($MILLION)

TABLE 112. LAMEA ANTIFUNGAL DRUGS MARKET, BY DOSAGE FORMS, 2020-2030,($MILLION)

TABLE 113. LAMEA ANTIFUNGAL DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 114. BRAZIL ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 115. BRAZIL ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 116. BRAZIL ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 117. BRAZIL ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 118. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 119. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 120. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 121. SAUDI ARABIA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 122. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 123. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 124. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 125. SOUTH AFRICA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 126. REST OF LAMEA ANTIFUNGAL DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 127. REST OF LAMEA ANTIFUNGAL DRUGS MARKET BY INFECTION TYPE 2020-2030,($MILLION)

TABLE 128. REST OF LAMEA ANTIFUNGAL DRUGS MARKET BY THERAPEUTIC INDICATIONS 2020-2030,($MILLION)

TABLE 129. REST OF LAMEA ANTIFUNGAL DRUGS MARKET BY DOSAGE FORMS 2020-2030,($MILLION)

TABLE 130.HOLOGIC, INC: COMPANY SNAPSHOT

TABLE 131.HOLOGIC, INC: OPERATING SEGMENTS

TABLE 132.HOLOGIC, INC: PRODUCT PORTFOLIO

TABLE 133.HOLOGIC, INC: NET SALES,

TABLE 134.HOLOGIC, INC: KEY STRATERGIES

TABLE 135.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT

TABLE 136.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS

TABLE 137.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO

TABLE 138.KONINKLIJKE PHILIPS N.V.: NET SALES,

TABLE 139.KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES

TABLE 140.QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT

TABLE 141.QUEST DIAGNOSTICS INCORPORATED: OPERATING SEGMENTS

TABLE 142.QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO

TABLE 143.QUEST DIAGNOSTICS INCORPORATED: NET SALES,

TABLE 144.QUEST DIAGNOSTICS INCORPORATED: KEY STRATERGIES

TABLE 145.SIEMENS MEDICAL SOLUTIONS USA, INC.: COMPANY SNAPSHOT

TABLE 146.SIEMENS MEDICAL SOLUTIONS USA, INC.: OPERATING SEGMENTS

TABLE 147.SIEMENS MEDICAL SOLUTIONS USA, INC.: PRODUCT PORTFOLIO

TABLE 148.SIEMENS MEDICAL SOLUTIONS USA, INC.: NET SALES,

TABLE 149.SIEMENS MEDICAL SOLUTIONS USA, INC.: KEY STRATERGIES

TABLE 150.BIOMÉRIEUX SA: COMPANY SNAPSHOT

TABLE 151.BIOMÉRIEUX SA: OPERATING SEGMENTS

TABLE 152.BIOMÉRIEUX SA: PRODUCT PORTFOLIO

TABLE 153.BIOMÉRIEUX SA: NET SALES,

TABLE 154.BIOMÉRIEUX SA: KEY STRATERGIES

TABLE 155.ABBOTT: COMPANY SNAPSHOT

TABLE 156.ABBOTT: OPERATING SEGMENTS

TABLE 157.ABBOTT: PRODUCT PORTFOLIO

TABLE 158.ABBOTT: NET SALES,

TABLE 159.ABBOTT: KEY STRATERGIES

TABLE 160.BD: COMPANY SNAPSHOT

TABLE 161.BD: OPERATING SEGMENTS

TABLE 162.BD: PRODUCT PORTFOLIO

TABLE 163.BD: NET SALES,

TABLE 164.BD: KEY STRATERGIES

TABLE 165.CARDINAL HEALTH, INC.: COMPANY SNAPSHOT

TABLE 166.CARDINAL HEALTH, INC.: OPERATING SEGMENTS

TABLE 167.CARDINAL HEALTH, INC.: PRODUCT PORTFOLIO

TABLE 168.CARDINAL HEALTH, INC.: NET SALES,

TABLE 169.CARDINAL HEALTH, INC.: KEY STRATERGIES

TABLE 170.F. HOFFMANN-LA ROCHE LTD : COMPANY SNAPSHOT

TABLE 171.F. HOFFMANN-LA ROCHE LTD : OPERATING SEGMENTS

TABLE 172.F. HOFFMANN-LA ROCHE LTD : PRODUCT PORTFOLIO

TABLE 173.F. HOFFMANN-LA ROCHE LTD : NET SALES,

TABLE 174.F. HOFFMANN-LA ROCHE LTD : KEY STRATERGIES

TABLE 175.GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT

TABLE 176.GENERAL ELECTRIC COMPANY: OPERATING SEGMENTS

TABLE 177.GENERAL ELECTRIC COMPANY: PRODUCT PORTFOLIO

TABLE 178.GENERAL ELECTRIC COMPANY: NET SALES,

TABLE 179.GENERAL ELECTRIC COMPANY: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.ANTIFUNGAL DRUGS MARKET SEGMENTATION

FIGURE 2.ANTIFUNGAL DRUGS MARKET,2020-2030

FIGURE 3.ANTIFUNGAL DRUGS MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.ANTIFUNGAL DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.ANTIFUNGAL DRUGS MARKET,BY DRUG CLASS,2020(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ECHINOCANDINS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF AZOLES ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF POLYENES ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ALLYLAMINES ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 18.ANTIFUNGAL DRUGS MARKET,BY INFECTION TYPE,2020(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SUPERFICIAL ANTIFUNGAL INFECTIONS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SYSTEMIC ANTIFUNGAL INFECTIONS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 21.ANTIFUNGAL DRUGS MARKET,BY THERAPEUTIC INDICATIONS,2020(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ASPERGILLOSIS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DERMATOPHYTOSIS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CANDIDIASIS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 26.ANTIFUNGAL DRUGS MARKET,BY DOSAGE FORMS,2020(%)

FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ORAL ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 28.COMPARATIVE SHARE ANALYSIS OF TOPICAL ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 29.COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIFUNGAL DRUGS MARKET,2020-2030(%)

FIGURE 30.ANTIFUNGAL DRUGS MARKET BY REGION,2020

FIGURE 31.U.S. ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 32.CANADA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 33.MEXICO ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 34.GERMANY ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 35.FRANCE ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 36.UNITED KINGDOM ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 37.ITALY ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 38.SPAIN ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 39.REST OF EUROPE ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 40.JAPAN ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 41.CHINA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 42.AUSTRALIA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 43.INDIA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 44.SOUTH KOREA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 45.REST OF ASIA-PACIFIC ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 46.BRAZIL ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 47.SAUDI ARABIA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 48.SOUTH AFRICA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 49.REST OF LAMEA ANTIFUNGAL DRUGS MARKET,2020-2030($MILLION)

FIGURE 50. TOP WINNING STRATEGIES, BY YEAR

FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 53.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 54.COMPETITIVE DASHBOARD

FIGURE 55.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 56.HOLOGIC, INC.: NET SALES ,($MILLION)

FIGURE 57.KONINKLIJKE PHILIPS N.V..: NET SALES ,($MILLION)

FIGURE 58.QUEST DIAGNOSTICS INCORPORATED.: NET SALES ,($MILLION)

FIGURE 59.SIEMENS MEDICAL SOLUTIONS USA, INC..: NET SALES ,($MILLION)

FIGURE 60.BIOMÉRIEUX SA.: NET SALES ,($MILLION)

FIGURE 61.ABBOTT.: NET SALES ,($MILLION)

FIGURE 62.BD.: NET SALES ,($MILLION)

FIGURE 63.CARDINAL HEALTH, INC..: NET SALES ,($MILLION)

FIGURE 64.F. HOFFMANN-LA ROCHE LTD .: NET SALES ,($MILLION)

FIGURE 65.GENERAL ELECTRIC COMPANY.: NET SALES ,($MILLION